Summary & Overview
CPT 36511: Leukapheresis (Removal of White Blood Cells)
CPT code 36511 represents leukapheresis, a therapeutic apheresis procedure that selectively removes white blood cells from a patient’s circulation and returns the remaining blood components. Leukapheresis is used in a range of clinical scenarios, including management of hyperleukocytosis, leukocyte reduction prior to chemotherapy, and select hematologic or immune-mediated conditions. Nationally, accurate reporting of CPT code 36511 is important for clinical documentation, utilization tracking, and payment processing for complex procedural care.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides readers with a concise clinical context for the procedure, common sites of service, and the scope of coverage considerations among major payers. It also outlines benchmark metrics and coding guidance relevant to billing and claims adjudication.
Readers will learn: the clinical definition and typical use cases for leukapheresis; expected sites of service and procedural setting; which major national payers are relevant to coverage and claims; and where to find benchmark and policy information when available. Data not available in the input includes specific payer policy details, associated taxonomies, ICD-10 diagnoses, and related billing codes.
Billing Code Overview
CPT code 36511 describes apheresis for removal of white blood cells (leukapheresis). Apheresis is a therapeutic procedure that uses specialized equipment to separate and remove selected blood constituents from whole blood and retransfuse the remainder to the patient. Report CPT code 36511 specifically for procedures that target removal of leukocytes.
Service type: Therapeutic apheresis (leukapheresis)
Typical site of service: Hospital inpatient or outpatient apheresis unit; specialized ambulatory infusion or procedure centers capable of apheresis
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with symptomatic hyperleukocytosis from acute myeloid leukemia presents to the hospital for therapeutic leukapheresis. The typical workflow begins with hematology consultation and order entry for 36511 (leukapheresis). Pre-procedure evaluation includes vitals, review of coagulation status, vascular access assessment, and informed consent. A central venous catheter or large-bore peripheral IV is placed or confirmed patent by interventional radiology or nursing staff. Laboratory studies (CBC, coagulation panel, basic metabolic panel) are reviewed and blood products or calcium supplementation are prepared to manage citrate toxicity. Apheresis nursing sets up the cell separator, programs the procedure for leukocyte removal, and monitors hemodynamics and anticoagulation throughout. The filtered blood components are discarded and the remainder is retransfused. Post-procedure monitoring includes repeat CBC to assess leukocyte reduction, assessment for procedure-related complications (hypocalcemia, bleeding, infection at access site), documentation of volumes processed and cells removed, and communication of results to the treating hematologist for next steps (additional apheresis sessions, chemotherapy initiation, or supportive care). Typical sites of service are inpatient hospital units, hospital outpatient infusion centers, and specialized apheresis suites. The service type is therapeutic apheresis (leukapheresis) billed under 36511.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|